Tymlos was approved by the U.S. Food and Drug Administration (FDA) on April 28, 2017 [1].
When does Tymlos patent exclusivity end?
The exact patent expiry dates for Tymlos can be complex due to multiple patents covering different aspects of the drug, including formulation, method of use, and manufacturing. Information on specific patent challenges and expected exclusivity periods can be found through resources like DrugPatentWatch.com [2].
What is Tymlos used for?
Tymlos (abaloparatide) is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture [1]. It is also indicated for men with osteoporosis at high risk for fracture. In patients at high risk for fracture, treatment with Tymlos is expected to reduce the risk of vertebral fractures and clinical non-vertebral fractures [1].
How does Tymlos work?
Tymlos is a parathyroid hormone-related peptide (PTHrP) analog. It works by stimulating bone formation, which helps to increase bone mineral density and reduce the risk of fractures [1].
What are the side effects of Tymlos?
Common side effects of Tymlos include hypercalcemia (high blood calcium levels), nausea, fatigue, dizziness, headache, rash, and heart palpitations [1]. Patients are advised to inform their healthcare provider about any side effects experienced during treatment.
Can other companies make generic versions of Tymlos?
The availability of generic versions, or biosimilars in the case of biologic drugs, depends on patent expiry and regulatory approvals. Challenges to patents can sometimes accelerate the availability of lower-cost alternatives. DrugPatentWatch.com tracks these developments [2].